A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)

Sponsor
Eli Lilly and Company
Study ID
NCT03951753
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
20 Years - 74 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a study for participants with type 2 diabetes mellitus. The main purpose of this study is to learn more about how tirzepatide, semaglutide and placebo affect the body's ability to respond to blood sugar levels after a meal. The study will last up to 40 weeks, including a 28-week treatment period.

Key Dates

Start date
Jun 28, 2019
Status verified
Jun 2022
Primary completion
Apr 8, 2021
Completion
Apr 8, 2021

Study Design

Enrollment
117 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Tirzepatide 15 mg
    Participants received 15 milligram (mg) tirzepatide administered subcutaneously (SC) once weekly for 28 weeks.
  • Active Comparator: Semaglutide 1 mg
    Participants received 1 mg Semaglutide administered SC once weekly for 28 weeks.
  • Placebo Comparator: Placebo
    Participants received Placebo administered SC once weekly for 28 weeks.

Primary Outcome Measure

Change From Baseline in Total Clamp Disposition Index (cDI) [ Time Frame: Baseline, Week 28 ]

Related Studies